Reproducibility of an assay to measure serum progesterone metabolites that may be related to breast cancer risk using liquid chromatographytandem mass spectrometry
Abstract: Recent data suggest a novel role of progesterone in breast cancer etiology involving the progesterone metabolites 3α-dihydroprogesterone (3αHP), 5α-dihydroprogesterone (5αP), and 20α-dihydroprogesterone (20αHP). Accurate and precise measures of progesterone metabolites are needed for etiologic studies of hormonally related cancers. We have developed a high-performance liquid chromatographytandem mass spectrometry (HPLC-MS/MS) method to measure five hormones, including progesterone, its precursor pregnenolone, and three progesterone metabolites, 5αP, 3αHP, and 20αHP. Hormone levels were measured in serum from 20 healthy volunteers (7 men, 5 premenopausal women, and 8 postmenopausal women). Two blinded, randomized aliquots per individual were assayed in each of four batches. The coefficients of variation (CV) and intraclass correlation coefficients (ICC) were calculated from the individual components of variance. The overall laboratory CVs were < 3% and ICCs were uniformly high ( > 98%) for all hormones measured across sex/menopausal status groups. Our HPLC-MS/MS assay of progesterone metabolites demonstrated excellent sensitivity, laboratory reproducibility, and interindividual variation, suggesting that this serum assay is suitable for epidemiologic research. The high sensitivity of the assay, and thus the ability to quantify concentrations among postmenopausal women and men, further supports that this novel assay is suitable for studies of serum progesterone metabolite concentrations and risk of breast cancer or other hormonally related cancer.
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A central role for both endogenous androgens and estrogens in the etiology of female cancers is well established by laboratory and epidemiologic evidence [1, 2] , while for men, evidence for a role of these hormones in prostate, testicular, and breast cancer carcinogenesis is suggestive [3] [4] [5] . However, the role of progesterone in cancer development is not clear. Some menopausal hormone formulations of estrogen plus progestin increase breast [6, 7] and ovarian cancer risk [8] but decrease endometrial cancer risk [9, 10] . The studies of menopausal hormone use and colon cancer also suggest a decreased risk with progestin exposure [11] [12] [13] .
In women, laboratory evidence implicates progesterone in the development of breast and possibly other tumors, but efforts to understand the mechanism of its action and to assess risk in populations independent of other hormones in the sex steroid pathway are challenging [14, 15] . Progesterone's actions are tissue-specific and occur in concert with other hormones; for instance, in women, along with estrogen, it is a proliferative agent in the normal breast, but not in the endometrium. Less is known of the role of progesterone in men, where it is produced by the adrenals and testes, and where levels are comparable to those in postmenopausal women.
Recent data suggest a novel role of progesterone in breast cancer etiology involving the progesterone metabolites 3α-dihydroprogesterone (3αHP), 5α-dihydroprogesterone (5αP), and 20α-dihydroprogesterone (20αHP). Laboratory studies by Wiebe and colleagues suggest that the relative concentration of cancer-inhibiting (3αHP) metabolites to cancer-promoting (5αP) metabolites may promote breast carcinogenesis [16] . Experimentally, 20αHP also demonstrates antimitogenic properties [17] and may selectively control aromatase activity [18] in breast cancer cell lines. Although ovary is the primary source of progesterone in premenopausal women, after menopause, much smaller amounts are produced in adipose tissue [19, 20] , and recent studies suggest that local production of 3αHP and 5αP metabolites may also occur in the breast [16] .
Few epidemiologic studies have investigated levels of endogenous progesterone in relation to cancer risk [21, 22] , in part, because current assays are not able to detect the low levels observed in the serum of postmenopausal women and men and require large sample volumes. In a study of postmenopausal breast cancer [21] , the limit of detection for the progesterone assay was 3 ng/dL and almost 30% of samples had undetectable levels. Furthermore, the available commercial kits measure only progesterone and do not measure additional metabolites that may play a role in the carcinogenic process.
In order to evaluate the role of progesterone and the metabolites 3αHP, 5αP, and 20αHP in large epidemiologic studies, accurate, sensitive, precise, and relatively simple laboratory methods that require small volumes of biological samples are needed. We have developed a stable isotope dilution liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method that requires 0.4 mL of serum to measure pregnenolone (progesterone precursor), progesterone, 5αP, 3αHP, and 20αHP ( Figure 1 ). The purpose of this report is to evaluate laboratory variability for the assay based on a formal reproducibility study in which blinded, randomized serum samples from men, premenopausal women, and postmenopausal women were assayed over several weeks and to assess the interindividual variability of metabolite levels by sex and menopausal status.
Hormone levels were measured in serum provided by 20 research donor. Donors included seven men aged from 35 to 63 years, five premenopausal women aged from to 36 years, and eight naturally postmenopausal women aged from to 65 years. Donors were identified only by code, and the specimens were further deidentified using laboratory accession numbers. Donors reporting the use of hormone supplements, oral contraceptives, or menopausal hormones within 3 months of blood draw were ineligible. Since the purpose of this study was to assess the performance of the assay method, we did not select donors based on other characteristics suspected of modifying pregnenolone/progesterone profiles, such as age, race, anthropometry, physical activity, diet, or stress. Details of our analytic method for measuring serum pregnenolone, progesterone, and three progesterone metabolites, including sample preparation, assay conditions, and internal standards are described in the online supplement. The steps included extraction with hexane, derivatization with hydroxylamine, followed by analysis with stable isotope dilution high-performance liquid chromatography-electrospray ionization tandem mass spectrometry (HPLC-MS/MS). Briefly, 20 μL of internal standard solution and 0.5 mL of freshly prepared phosphate-buffered normal saline solution were added to 0.4 mL human serum. Following inverse extraction with 5 mL hexane for 30 min, the sample was transferred to a clean glass tube and evaporated to dryness at 60°C under a stream of nitrogen gas. Then dried sample was then derivatized using 100 μL of 0.1 M hydroxylamine solution with 5% acetic acid and heated at 60°C for 30 min to form the oxime derivatives of hormone metabolites and their stable isotope labeled internal standards. After derivatization, all samples were analyzed by HPLC-MS/MS selected reaction monitoring (SRM) in positive-ion mode using a Thermo TSQ TM Vantage triple quadrapole mass spectrometer (Thermo Scientific, San Jose, CA, USA) coupled with a prominence UFLC system (Shimadzu Scientific Instruments, San Jose, CA, USA) and quantified using Xcaliber TM Quan Browser (Thermo Scientific). During oxime derivatization of ketosteroids such as those analyzed in this study, two geometric stereoisomers can be formed from a single ketosteroid. To avoid undesirable twin peaks for a single steroid, the chromatography condition described in this manuscript ensures each metabolite is eluted as a single oxime-derivatized ketosteroid peak.
All calibration and quality control samples in double charcoal-stripped human serum were prepared following the same procedures as that of unknown serum samples. Analyses of calibration and quality control samples for the hormones measured performed well, suggesting excellent assay accuracy, precision, and quantitative ranges. The lower limit of quantitation is 0.5 ng/dL and the limit of detection is 0.1 ng/dL.
Interindividual differences in the distribution of pregnenolone/progesterone measurements across sex/ menopausal status groups were compared using box plots. Hormone values were log transformed to stabilize variances. To quantify reproducibility of the pregnenolone/progesterone assays, estimates of the variability among subjects, assay variability among batches for a given subject, and assay variability associated with different aliquots in the same batch for the same subject were obtained using a nested component of variance analysis.
Using the variance estimates, we computed the overall coefficients of variation (CV) and intraclass correlation coefficient (ICC) for each sex/menopausal status group.
The serum levels of the hormones measured by HPLC-MS/MS in 20 research donor samples are shown in Table 1 . Of the hormones measured, 3αHP was consistently the lowest concentration metabolite in circulation by rank across all sex/menopausal status groups. The ranking of the other hormones measured varied across groups. Figure 2 graphically summarizes the design of the reproducibility study for each of the five hormones measured by sex/menopausal status. The hormone concentrations are plotted on the y-axis by batch on the x-axis. The blinded duplicates for each hormone measured are shown for men and postmenopausal women, respectively. A similar plot for premenopausal women is provided in Supplemental Figure 1 . The overall laboratory CVs were < 3% and the ICCs were exceptionally high ( > 99.0%) for all hormones measured across sex/menopausal status group (Table 2) .
For 3αHP, we observed values below the lower limit of quantitation for the assay (0.50 ng/dL) for one man (3αHP = 0.45 ng/dL) and two postmenopausal women (3αHP = 0.28 and 0.47 ng/dL); however, all values were above the lower limit of detection (0.10 ng/dL). All other hormone levels measured were above the lower limit of quantitation for the assay, even among postmenopausal women, where levels are presumed to be the lowest.
Our novel, HPLC-MS/MS assay of pregnenolone, progesterone, and three progesterone metabolites demonstrated excellent laboratory reproducibility. The uniformly high ICCs for the metabolites measured suggest that interindividual variability was much greater than laboratory variation, even in postmenopausal women and men, where circulating levels are low. We also observed substantial interindividual variability of circulating levels of the three progesterone metabolites measured as well as progesterone precursor pregnenolone across sex/menopausal status groups. Given that our results are based on a small number of participants (n = 20), it is possible that the variance estimates may not adequately represent the underlying population values and provide imprecise estimates of the relevant statistics. However, the excellent reproducibility, sensitivity, and high ICCs across all sex/menopausal status groups, especially among postmenopausal women and men where concentrations are lowest, are notable. The small number of subjects in each sex/menopausal status group also limits our ability to explore hormone profiles with clinical, demographic, and anthropometric characteristics and argues for the need to evaluate these associations in large population-based studies. Finally, the use of single blood draw from research donors does not address intraindividual variation in progesterone metabolite profiles.
In conclusion, our findings of excellent laboratory reproducibility and interindividual variation in progesterone metabolites suggest that this serum assay is suitable for use in epidemiologic research. Moreover, the high sensitivity of the assay, and thus the ability to quantify concentrations among postmenopausal women and men, further supports that this assay may be suitable for studies of serum progesterone metabolite concentrations and the risk of breast cancer or other hormonally related cancer.
